AGF Management Ltd. Sells 25,865 Shares of Johnson & Johnson (NYSE:JNJ)

AGF Management Ltd. lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 573,876 shares of the company's stock after selling 25,865 shares during the quarter. AGF Management Ltd.'s holdings in Johnson & Johnson were worth $82,994,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in JNJ. IFS Advisors LLC lifted its stake in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $32,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth about $35,000. Activest Wealth Management bought a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $40,000. Finally, NewSquare Capital LLC lifted its stake in shares of Johnson & Johnson by 145.8% during the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company's stock valued at $42,000 after buying an additional 172 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business's stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Remove Ads

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Morgan Stanley decreased their price objective on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Barclays boosted their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Bank of America upped their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a report on Wednesday, March 5th. Finally, Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $171.33.

Johnson & Johnson Trading Down 1.1 %

Johnson & Johnson stock traded down $1.84 during mid-day trading on Tuesday, hitting $165.86. The company's stock had a trading volume of 9,890,083 shares, compared to its average volume of 7,092,055. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business has a 50 day moving average price of $153.86 and a 200-day moving average price of $156.29. The stock has a market cap of $399.33 billion, a price-to-earnings ratio of 24.94, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.29 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 2.99%. Johnson & Johnson's payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.